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Abstract
Background: Both vitamin D deficiency and genetic variants in the vitamin D receptor (VDR) have been reported
to associate with delayed response to intensive-phase therapy for pulmonary tuberculosis. Studies investigating the
influence of genetic variants in vitamin D binding protein (DBP) and vitamin D 25-hydroxylase (CYP2R1) on vitamin
D status and response to antituberculous therapy are lacking.
Methods: We conducted a longitudinal study in 260 patients initiating treatment for smear-positive
pulmonary tuberculosis in Lahore, Pakistan. Vitamin D status and genotypes for polymorphisms in VDR
(rs2228570, rs731236, rs1544410), DBP (rs7041, rs4588) and CYP2R1 (rs2060793, rs10500804, rs10766197) were
determined at baseline. Sputum smear microscopy was performed at 2, 4, 6 and 8 weeks, and time to sputum smear
conversion was estimated for each participant. Analyses were conducted to determine demographic, clinical and
genetic determinants of baseline vitamin D status and time to sputum smear conversion.
Results: Profound vitamin D deficiency (serum 25[OH]D < 25 nmol/L) was highly prevalent at TB diagnosis (present
in 54 % of patients), and was independently associated with female vs. male sex (adjusted OR 2.60, 95 % CI 1.50 to
4.52, P = 0.001), recruitment in October to March inclusive (adjusted OR 1.75, 95 % CI 1.00 to 3.04, P = 0.047) and
bilateral vs. unilateral disease (adjusted OR 1.89, 95 % CI 1.49 to 4.52 P = 0.025). Profound vitamin D deficiency was
also independently associated with impaired response to antituberculous therapy (median time to sputum smear
conversion 22.5 vs. 7.5 days for patients with serum 25[OH]D <25 nmol/L vs. ≥ 25 nmol/L, respectively; aHR 4.36,
95 % CI 3.25 to 6.65, P < 0.001). No polymorphisms in VDR, CYP2R1 and DBP studied associated with either baseline
vitamin D status or time to sputum smear conversion.
Conclusions: Profound vitamin D deficiency is very common among TB patients in Lahore, Pakistan, and is
independently associated with significantly delayed sputum smear conversion. Polymorphisms in VDR, CYP2R1 and
DBP did not associate with baseline vitamin D status or response to intensive-phase treatment in this patient
group.
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Background
Despite widespread availability of antimicrobial therapy,
tuberculosis continues to carry a significant case fatality
rate, estimated at 4–7 % in notified HIV-uninfected
cases [1]. An improved understanding of the risk factors
for poor response to antituberculous therapy could lead
to the development of new interventions to improve
treatment outcome.
A growing body of evidence suggests that vitamin D
deficiency may be one such factor [2]. High-dose vitamin
D was used to treat tuberculosis in the pre-antibiotic
era, [3] and vitamin D metabolites support the induction
of a broad range of antimycobacterial effector responses
in vitro [4–8]. Vitamin D deficiency associates with im-
paired response to antituberculous therapy [9–11]. Gen-
etic variants in the vitamin D receptor (VDR), which
transduces vitamin D signal to modify transcriptional re-
sponses, have also been reported to predict treatment re-
sponse [12, 13]. Polymorphisms in the vitamin D
binding protein (DBP), which transports vitamin D me-
tabolites in the circulation, and the vitamin D 25-
hydroxylase enzyme (CYP2R1), which converts ‘parent’
vitamin D to its major circulating metabolite 25-
hydroxyvitamin D (25[OH]D), influence vitamin D sta-
tus in the general population [14]. However, their poten-
tial influence on vitamin D status and response to
antimicrobial therapy in TB patients has not previously
been studied. Moreover, despite evidence that effects of
vitamin D status on the response to M. tuberculosis are
genotype-dependent, [15–17] studies investigating the
potential effect of interactions between vitamin D status
and polymorphisms in the vitamin D pathway on re-
sponse to antituberculous therapy have not previously
been performed. We therefore conducted an observa-
tional study to determine a) the prevalence and determi-
nants of vitamin D deficiency among a cohort of
patients with newly-diagnosed pulmonary tuberculosis
in Lahore, Pakistan; b) whether baseline vitamin D status
and / or polymorphisms in VDR, DBP or CYP2R1 asso-
ciated with response to intensive-phase antituberculous
therapy in these patients as main effects, and c) whether
any associations between vitamin D deficiency and re-
sponse to treatment were genotype-dependent.
Methods
Study population
Patients attending Gulab Devi Chest Hospital, Lahore,
Pakistan (Latitude 31.5° N) for treatment of smear-
positive pulmonary tuberculosis were screened for eligi-
bility to participate in the study. The following were ex-
cluded: those aged less than 14 years or more than
60 years; those who had already initiated antituberculous
therapy; those with a medical record diagnosis of type 1
or type 2 diabetes mellitus, chronic renal failure, hepatic
failure or ischaemic heart disease; and those with sero-
logical evidence of Hepatitis B, Hepatitis C or HIV infec-
tion. Those fulfilling eligibility criteria completed a
questionnaire detailing age, gender and socioeconomic
status (as indicated by whether or not they were in receipt
of financial aid for hospital costs). All participants had a
chest radiograph at baseline, which was classified as show-
ing either unilateral or bilateral disease by the consultant
chest physician in charge of their care. Participants also
gave a sputum sample (for microscopy +/− mycobacterial
culture as detailed below) and a 5 ml blood sample at
baseline. Half of this blood sample was drawn into a
serum tube, and the half was drawn into an EDTA tube.
Serum tubes were centrifuged, and serum was aspirated
and stored at −20 °C for subsequent assay of 25(OH)D
concentration. Whole blood in EDTA was stored at 4 °C
for subsequent DNA extraction. Participants whose base-
line blood sample was haemolysed were excluded from
analyses. Participants then initiated directly-observed anti-
tuberculous treatment according to WHO guidelines [18]
and were followed up 2, 4, 6 and 8 weeks later. At each
time point they were asked to provide a repeat sputum
sample for microscopy, until either their sputum sample
was smear-negative, or they were unable to expectorate.
Data from patients who attended their final follow-up visit
late were included up to 10 weeks from initiation of anti-
microbial treatment. Medical staff caring for participants
were informed of their patients’ vitamin D status at the
end of the study, and were free to manage this as they
deemed appropriate after the participant had completed
follow-up. The study was approved by the ethics commit-
tees of the School of Biological Sciences, University of
Punjab (ref SBS 873–12) and of the Gulab Devi Chest
Hospital, Lahore. All participants gave informed consent
to take part.
Laboratory methods
Microscopy of Ziehl-Nielsen (ZN) -stained sputum sam-
ples was performed in the Microbiology Laboratory at
the Gulab Devi Chest Hospital by trained staff using
written standard operating procedures. These staff were
blinded to participants’ vitamin D status. Bacillary load
in baseline sputum samples was classified according to
the number of acid-fast bacilli seen per high power field
(HPF). Mycobacterial culture and drug sensitivity testing
was done for a sub-group of patients who fulfilled hos-
pital criteria for performing this test, namely those who
were sputum-smear positive after 2 weeks of intensive-
phase anti-TB treatment, and who had either been previ-
ously treated for tuberculosis or who were known to
have had contact with patients with confirmed MDR-TB.
Sputum samples from patients selected for drug sensitiv-
ity testing were initially assessed using the GeneXpert
MTB/RIF platform [19]. Samples which were positive on
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this molecular test were then cultured on Lowenstein
Jensen medium, and colonies were sent for phenotypic
drug sensitivity testing using the Bactec MGIT system as
described [20]. Serum 25(OH)D concentrations were de-
termined by ELISA (Immunodiagnostic Systems, Boldon,
UK); the inter-assay coefficient of variation was 11.5 %,
and the average duration of sample storage prior to
25(OH)D assay was 91.2 days. Profound vitamin D de-
ficiency was defined as a serum 25(OH)D concentra-
tion <25 nmol/L. Genomic DNA was extracted from
whole blood [21] and quantified using the Nanodrop
spectrophotometer and normalised to 5 ng/μl. 10 ng
DNA was used as template for 2 μl TaqMan allelic
discrimination assays (Applied Biosystems, Foster
City, CA, USA) performed on the ABI 7900HT plat-
form in 384-well format and analysed with Autocaller
software, as previously described [22]. Pre-developed
assays were used to type polymorphisms in genes en-
coding VDR (rs2228570 [FokI], rs731236 [TaqI] and
rs1544410 [BsmI]), CYP2R1 (rs2060793, rs10500804
and rs10766197) and DBP (rs7041 [HaeIII] and
rs4588 [StyI]). Genotyping assays failed in a small
proportion of subjects, possibly as a result of poor
DNA quality. Alleles at all loci conformed to the
Hardy-Weinberg equilibrium.
Sample size and statistical analyses
The study was prospectively powered to estimate preva-
lence of profound vitamin D deficiency in the study
population with a 5 % error margin at the 95 % confi-
dence level, using published algorithms [23]. Assuming
an expected frequency of 79 %, [24] we calculated that a
total of n = 253 participants would need to be recruited.
Statistical analyses were done with SPSS (version 20.0)
and Stata IC (version 12) and figures were prepared with
GraphPad Prism (version 4.00). The date of sputum
smear conversion was estimated as the midpoint be-
tween the date of the last positive sputum smear and the
date of the first negative sputum smear thereafter. Time
to sputum smear conversion was calculated as the num-
ber of days from the date on which antituberculous
treatment was initiated to the estimated date of sputum
smear conversion.
Univariate analysis of associations between potential
determinants of vitamin D status and risk of profound
vitamin D deficiency was done using chi square tests;
those found to associate with P < 0.1 on univariate
analysis were included in multivariate analysis, which
was done with binary logistic regression. Analysis of
determinants of time to sputum smear conversion
was done using Cox regression. Sub-group analyses to
test for gene-environment interactions were per-
formed by Cox regression with the inclusion of inter-
action terms between genotype and vitamin D status
(25[OH]D < 25 nmol/L vs. ≥ 25 nmol/L); for these
analyses, the Benjamini-Hochberg procedure for multiple
testing correction was applied to control the false discov-
ery rate with a q value threshold of 0.2 [25]. For all ana-
lyses, the influence of potential genetic determinants on
dependent variables was assessed using additive models.
Interaction effects were summarised as a ratio of hazard
ratios with 95 % confidence interval and P-value. Statis-
tical significance was assumed where P < 0.05.
Results
Participant enrolment and follow-up
Three hundred patients with smear-positive pulmonary
TB fulfilling study eligibility criteria were recruited to
the study from the Gulab Devi Chest Hospital, Lahore,
Pakistan between August 2012 and November 2013. Of
these, 40 were excluded from the analysis, 26 due to
sampling after the start of antituberculous treatment and
14 due to haemolysis of blood samples. Of the remaining
260 patients, 248 completed follow-up, 10 were lost to
follow-up and 2 died (Fig. 1).
Baseline characteristics of study participants
The mean age of the 260 participants entering analysis
was 31.6 years (standard deviation 10.5 years, range 14
to 55 years), and 140 (54 %) were female. One hundred
and thirty seven patients (53 %) were enrolled in the
sunnier part of the year (April to September inclusive),
and 123 (47 %) were enrolled in the less sunny part of
the year (October to March inclusive). One hundred and
forty-four patients (55 %) had unilateral disease on chest
radiograph, and 116 (45 %) had bilateral disease.
Seventy-two patients (28 %) fulfilled hospital criteria for
performing drug sensitivity testing, of whom 56 (78 %)
had fully-sensitive disease and 16 (22 %) had MDR TB.
Vitamin D deficiency was highly prevalent at baseline:
140 patients (54 %) had serum 25(OH)D < 25 nmol/L,
97 (37 %) had serum 25(OH)D 25–49.9 nmol/L, 17
(7 %) had serum 25(OH)D 50–74.9 nmol/L and only 6
(2 %) had serum 25(OH)D ≥75 nmol/L (Table 1). Me-
dian 25(OH)D concentration was 23.3 nmol/L (inter-
quartile range 16.0 to 34.0 nmol/L).
Determinants of baseline vitamin D status
Phenotypic and genotypic determinants of baseline vita-
min D status are presented in Table 2. Multivariate ana-
lysis revealed independent associations between profound
vitamin D deficiency (serum 25[OH] D < 25 nmol/L) and
female sex (aOR 2.60, 95 % CI 1.50 to 4.52, P = 0.001); re-
cruitment between October and March, inclusive (aOR
1.75, 95 % CI 1.00 to 3.04. P = 0.047); and bilateral disease
(aOR 1.89, 95 % CI 1.49 to 4.52, P = 0.025; Fig. 2). No in-
dependent associations were observed between baseline
vitamin D status and age, socio-economic status, degree
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of smear-positivity at baseline or any polymorphism
studied.
Determinants of time to sputum smear conversion
Phenotypic and genotypic determinants of time to
sputum smear conversion are presented in Table 3.
Multivariate analysis adjusting for sex, radiological ex-
tent of disease, baseline vitamin D status and drug
sensitivity revealed independent associations between
delayed sputum smear conversion and profound vita-
min D deficiency at baseline (aHR 4.36, 95 % CI 3.25
to 6.65, P < 0.001). Isolation of a multidrug-resistant
organism on sputum culture was also independently
associated with delayed sputum smear conversion
(aHR 3.35, 95 % CI 1.71 to 6.54, P < 0.001)(Fig. 3).
No independent associations were observed between
delayed sputum smear conversion and socio-economic
status, radiographic extent of disease, age or any poly-
morphism investigated.
In order to investigate the possibility that the pres-
ence of undiagnosed MDR-TB may have confounded
the relationship between low baseline vitamin D status
and delayed sputum culture conversion, we repeated
the multivariate Cox regression analysis of determinants
of time to sputum smear conversion in the sub-group
of 72 patients for whom DST results were available,
adjusting for sex, radiological extent of disease, baseline
vitamin D status and drug sensitivity as before. The
independent association between low baseline vitamin D
status and delayed sputum smear conversion remained
strong after adjustment for sex, radiological extent of dis-
ease and drug sensitivity (adjusted Hazard Ratio [aHR]
4.51, 95 % CI 1.91 to 10.70, P = 0.001). The independent
association between presence of MDR TB and delayed
sputum smear conversion was also replicated in this sub-
group analysis (aHR 3.59, 95 % CI 1.77 to 7.30, P < 0.001).
The findings of this sub-group analysis suggest that the as-
sociation between low vitamin D status and delayed spu-
tum smear conversion seen in the study population as a
whole are likely to be independent of the effects of MDR
TB on this outcome.
Influence of gene-environment interaction on time to
sputum conversion
We have previously reported that polymorphisms in
the vitamin D receptor modify the effect of vitamin D
supplementation on time to sputum culture conver-
sion [17]. We were therefore interested to determine
whether the strength of association between profound
vitamin D deficiency and delayed sputum smear con-
version differed according to genetic variation in
VDR, DBP and CYP2R1. Results of the pertinent
interaction analyses are presented in Table 4. Prior to
correction for multiple analyses, statistically significant
associations between profound vitamin D deficiency
and delayed sputum smear conversion were found in
Fig. 1 Participant enrolment and follow-up
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patients with the GG genotype of rs2228570,VDR (ad-
justed HR 6.53, 95 % CI 3.99 to 10.66, P < 0.001) and
in those with the GA genotype (adjusted HR 3.02,
95 % CI 1.82 to 5.01, P < 0.001) but not in those with
the AA genotype (adjusted HR 4.58, 95 % CI 0.56 to
37.25, P = 0.16; P for interaction = 0.03). However, this
interaction did not attain statistical significance after
correction for multiple analyses. P values for the
interaction terms for all other genotypes were >0.05.
Discussion
To our knowledge, this is the first study to investigate po-
tential interactions between vitamin D status and poly-
morphisms in the vitamin D pathway on the response to
antituberculous therapy. We report that profound vitamin
D deficiency is highly prevalent among newly-diagnosed
TB patients in Pakistan, and that it is strongly and inde-
pendently associated with markedly delayed sputum
smear conversion. By contrast, polymorphisms in genes
encoding VDR, DBP and CYP2R1 did not influence either
vitamin D status or response to antituberculous therapy as
main effects.
The high prevalence of profound vitamin D deficiency
that we report among TB patients is striking, especially
given that Lahore is located at 31.5° N, a latitude at
which the intensity of ultraviolet radiation should be suf-
ficient to induce cutaneous vitamin D synthesis year-
round [26]. The mean serum 25(OH)D concentration
among patients in our study (27.3 nmol/L) was lower
than that reported in TB patients elsewhere in Punjab
province, Pakistan (57.4 nmol/L), [27] and lower than
that found among HIV-uninfected adults with active TB
in Cape Town (40.5 nmol/L), [28] a sub-tropical setting
that is approximately equidistant from the equator (lati-
tude 33.9°S). In both of these case–control studies, vita-
min D status was found to be lower among TB patients
vs. controls. We hypothesise that low serum 25(OH)D
concentrations may have preceded the onset of active
TB, and impaired containment of latent TB infection,
thereby leading to the development of active TB. This
hypothesis is supported by findings of longitudinal stud-
ies conducted in Pakistan [24] and elsewhere [11]
reporting that vitamin D deficiency in patients at risk of
active TB precedes the development of active disease.
However, reverse causality or residual confounding can-
not be ruled out as explanations for this association, and
trials of vitamin D for TB prevention are needed in
order to determine whether vitamin D deficiency is a
cause, rather than a consequence, of active TB. The co-
existence of a high prevalence of vitamin D deficiency
and high incidence of tuberculosis in sub-tropical set-
tings such as Pakistan and South Africa makes them ap-
propriate settings for such trials to be conducted. We
also noted that vitamin D deficiency was more prevalent
among female vs. male participants in our study; this
may be attributable to sex differences in sun exposure
and/or dietary vitamin D intake.
Our finding that vitamin D deficiency associates with
impaired response to antituberculous therapy is consist-
ent with reports from other observational studies to in-
vestigate this question. Rathored et al. reported an
inverse association between serum 25(OH)D concentra-
tion and time to sputum smear conversion among
354 patients with multidrug-resistant tuberculosis in
New Delhi, India [9]. Sato et al. reported a similar as-
sociation among 34 patients with drug-sensitive dis-
ease in Fukushima, Japan [10]. More recently, Mehta
et al. reported that vitamin D insufficiency (serum
25[OH]D <75 nmol/L) associated with increased risk
of treatment relapse in a cohort of TB patients in
Tanzania [11]. The consistency of this association in
observational studies contrasts with findings of rando-
mised controlled trials of adjunctive vitamin D to en-
hance response to antituberculous treatment, which
have been more variable, [17, 29–32] although it is
worth noting that studies utilising higher doses of vita-
min D have reported acceleration of sputum smear
conversion by around 2 weeks [29, 33] – similar to the
Table 1 Demographic and clinical characteristics of study
participants at baseline (n = 260)
Age Mean age, years (s.d.) .31.6 (10.5)
Age range, years 14 to 55
Sex Male, N (%) 120 (46 %)
Female, N (%) 140 (54 %)
Socioeconomic statusa Lower, N (%) 177 (68 %)
Higher, N (%) 83 (32 %)
Month of recruitment April - September, N (%) 137 (53 %)
October - March, N (%) 123 (47 %)
Sensitivity profile Fully-sensitive 56 (22 %)
Multidrug-resistant 16 (6 %)
Undetermined 188 (72 %)
Extent of disease Unilateral 144 (55 %)
Bilateral 116 (45 %)
Sputum smear 1–99 AFB per 100 HPF 177 (68 %)




Median, nmol/L (IQR) 23.3 (16.0 to 34.0)
<25 nmol/L, N (%) 140 (54 %)
25.0 to 49.9 nmol/L, N (%) 97 (37 %)
50.0 to 74.9 nmol/L, N (%) 17 (7 %)
≥75.0 nmol/L, N (%) 6 (2 %)
AFB acid-fast bacilli, HPF high-power microscopy fields
aLower socioeconomic status indicated by patient being in receipt of financial
aid for hospital costs
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Table 2 Determinants of baseline Vitamin D status (n = 260)
Univariate Multivariate
N 25(OH)D <25 nmol/L,
N (%)





Sex Male 120 49 (41 %) Ref Ref
Female 140 91 (65 %) 2.67 (1.62 to 2.45) <0.001 2.60(1.50 to 4.52) 0.001
Season of recruitment Summer 137 66 (48 %) Ref Ref
Winter 123 74 (60 %) 1.62 (0.99 to 2.65) 0.053 1.75 (1.00 to 3.04) 0.047
Socioeconomic statusb Lower 177 96 (54 %) Ref
Higher 83 44 (53 %) 0.95 (0.56 to 1.60) 0.85 - -
Extent of disease Unilateral 144 67 (46 %) Ref Ref
Bilateral 116 73 (63 %) 1.95 (1.18 to 3.21) 0.009 1.89 (1.49 to 4.52) 0.025
Sputum smear 1–99 AFB per 100 HPF 106 53 (50 %) Ref
≥100 AFB per 100 HPF 154 87 (56 %) 0.74 (0.45 to 1.22) 0.24 - -
Age <30 years 124 67 (54 %) Ref
≥30 years 136 73 (54 %) 0.98 (0.60 to 1.60) 0.95 - -
Genotypic
characteristics
rs731236, VDR AA 83 38 (46 %) Ref 0.14
AG 115 67 (58 %) 1.65 (0.93 to 2.92) - -
GG 27 17 (63 %) 2.01 (0.82 to 4.91) - -
rs1544410,VDR CC 53 23 (43 %) Ref 0.098
CT 128 74 (58 %) 1.78 (0.94 to 3.41) 1.66 (0.84 to 3.28) 0.14
TT 54 34 (63 %) 2.21 (1.02 to 4.81) 2.23 (0.98 to 5.05) 0.054
rs2228570,VDR GG 137 76 (55 %) Ref 0.96
GA 83 47 (57 %) 1.04 (0.60 to 1.81) - -
AA 15 8 (53 %) 0.92 (0.31 to 2.67) - -
rs2060793, CYP2R1 GG 112 62 (55 %) Ref 0.81
AG 106 62 (58 %) 0.80 (0.22 to 2.94) - -
AA 10 5 (50 %) 1.13 (0.66 to 1.94) - -
rs10500804, CYP2R1 GG 59 34 (58 %) Ref 0.34
GT 120 69 (58 %) 0.99 (0.53 to 1.87) - -
TT 52 24 (46 %) 0.63 (0.29 to 1.33) - -
rs10766197, CYP2R1 AA 52 29 (56 %) Ref 0.60
AG 124 72 (58 %) 1.18 (0.57 to 2.11) - -
GG 56 28 (50 %) 0.84 (0.37 to 1.72) - -
rs7041, DBP AA 55 34 (62 %) Ref 0.57
AC 106 57 (54 %) 0.72 (0.37 to 1.47) - -
CC 71 38 (54 %) 0.71 (0.34 to 1.45) - -
rs4588,DBP GG 122 66 (54 %) Ref 0.14
GT 91 49 (54 %) 0.99 (0.57 to 1.70) - -
TT 21 16 (76 %) 2.71 (0.93 to 7.88) - -
25(OH)D 25-hydroxyvitamin D, OR odds ratio, Ref referent category, AFB acid-fast bacilli, HPF high-power fields, VDR vitamin D receptor, CYP2R1 vitamin D
25-hydroxylase, DBP vitamin D binding protein
aadjusted for sex, season of recruitment, extent of disease and rs1544410 genotype. blower socioeconomic status indicated by patient being in receipt of financial
aid for hospital costs
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15 day difference in time to conversion reported in this
study. Potential reasons for the discrepancy between ob-
servational studies and clinical trials could be explained
by residual confounding in observational studies; in-
appropriate dosing regimens administered in clinical tri-
als (doses either too small or too widely spaced to
cause sustained elevation of serum 25[OH]D concentra-
tion); or insufficient power to detect potentially modest
effects in drug-sensitive disease. At least three more tri-
als with generous dosing regimens and/or larger sam-
ple sizes are in progress (ClinicalTrials.gov references
NCT01657656, NCT01580007 and NCT00507000),
and their results are awaited with interest.
Our finding that commonly-studied polymorphisms
in the vitamin D receptor did not influence time to
sputum smear conversion contrasts with studies that
have variously reported associations with rs2228570
(FokI), [34] rs731236 (TaqI), [13, 34] and rs1544410
(BsmI) [9]. Moreover, we did not find any association be-
tween polymorphisms in CYP2R1 or DBP and treatment
response. Based on our previous findings suggesting clin-
ically important gene-environment interactions in this
context [15–17] we went on to explore the possibility that
genetic variation in the vitamin D pathway might modify
the influence of vitamin D status on response to antituber-
culous treatment : sub-group analyses revealed the persist-
ence of very strong associations between vitamin D
deficiency and delayed smear conversion across genotypic
sub-groups. Overall, our results suggest that the strong
phenotypic influence of profound vitamin D deficiency
appears to outweigh any more subtle effect of genotypic
variation in the vitamin D pathway on response to anti-
tuberculous therapy.
Our study has several strengths: our investigation of
the influence of gene-environment interactions in the
vitamin D pathway on response to antituberculous ther-
apy is novel, as is our investigation of polymorphisms in
CYP2R1 and DBP. Loss to follow-up was low (<5 %) and
antituberculous treatment was directly observed. More-
over, phenotypic and genotypic data were available to
Fig. 3 Time to sputum smear conversion by baseline vitamin D status (a) and drug sensitivity of M. tuberculosis isolate (b). Numbers of patients
with positive sputum smear remaining in follow-up (number at risk) at 0, 14, 28, 42, 56 and 70 days are shown
Fig. 2 Serum 25-hydroxyvitamin D concentration for n = 260 study participants by sex (a), extent of disease (b) and season (c). P values from
binary logistic regression adjusted for sex, extent of disease, season of enrolment and BsmI vitamin D receptor genotype
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Table 3 Determinants of time to sputum smear conversion (n = 260)
Univariate analysis Multivariate analysis
N Median TTSC,
days (IQR)
HR (95 % CI) P Adjusted




Sex Male 120 7.5 (7.5–22.5) 1.47 (1.11–1.80) 0.01 1.16 (0.91–1.51) 0.26
Female 140 22.5 (7.5–35) Ref - Ref -
Socioeconomic statusb Lower 177 21 (7.5–30) 0.96 (0.73–1.23) 0.68 - -
Higher 83 21 (7.5–22.5) Ref - - -
Extent of disease Unilateral 144 7.5 (7.5–22.5) 1.38 (1.07–1.78) 0.01 1.21(0.85–1.55) 0.23
Bilateral 116 22.5 (7.5–36.5) Ref - Ref -
Sputum smear 1–99 AFB per 100 HPF 106 7.5 (7.5–22.5) 0.80 (0.6–1.01) 0.60 - -
≥100 AFB per 100 HPF 154 22.5 (7.5–23) Ref - - -
Age <30 years 124 21 (7.5–22.5) 1.14 (0.91–1.50) 0.33 - -
≥30 years 136 22 (7.5–37.5) Ref - - -
25(OH)D <25 nmol/l 140 22.5 (22.5–37.5) 4.93 (3.55–6.86) <0.001 4.36(3.25–6.65) <0.001
≥25 nmol/l 120 7.5 (7.5–7.5) Ref - Ref -
Drug sensitivity Fully–sensitive / unknown 244 15 (7.5–22.5) Ref - Ref -
Multidrug–resistant 16 52.5 (Undefined–35) 3.92 (2.12–7.24) <0.001 3.35 (1.71–6.54) <0.001
Genotypic
characteristics
rs731236, VDR AA 84 7.5 (7.5–22.5) 0.87 (0.71–1.06) 0.16 - -
AG 117 21 (7.5–30)
GG 29 22.5 (7.5–37.5)
rs1544410,VDR CC 53 7.5 (7.5–22.5) 0.89 (0.73–1.08) 0.26 - -
CT 128 21 (7.5–35)
TT 54 21.5 (7.5–23)
rs2228570,VDR GG 138 15 (7.5–23) 1.04 (0.84–1.28) 0.70 - -
GA 83 22.5 (7.5–22.5)
AA 15 7.5 (7.5–22.5)
rs2060793,CYP2R1 AA 10 21 (7.5–22.5) 0.88 (0.69–1.11) 0.28 - -
AG 106 21 (7.5–23)
GG 112 21 (7.5–23)
rs10500804,CYP2R1 GG 59 15 (7.5–22.5) 1.12(0.92–1.38) 0.24 - -
GT 120 22.5 (7.5–35)
TT 52 7.5 (7.5–22.5)
rs10766197,CYP2R1 AA 52 15 (7.5–22.5) 1.13 (0.92–1.38) 0.24 - -
AG 124 22.5 (7.5–35)
GG 56 15 (7.5–22.5)
rs7041,DBP AA 55 22.5 (7.5–22.5) 1.0 (0.83–1.21) 0.94 - -
AC 106 15 (7.5–22.5)
CC 71 7.5 (7.5–23)
rs4588,DBP GG 122 21 (7.5–23) 1.01 (0.82–1.23) 0.90 - -
GT 91 15 (7.5–22.5)
TT 21 22.5 (15–22.5)
TTSC time to sputum smear conversion, IQR interquartile range, HR hazard ratio, Ref referent category, AFB acid–fast bacilli, HPF high–power microscopy fields,
25(OH)D 25–hydroxyvitamin D, VDR vitamin D receptor, CYP2R1 vitamin D 25–hydroxylase, DBP vitamin D binding protein
aadjusted for sex, extent of disease, baseline vitamin D status and drug sensitivity; blower socioeconomic status indicated by patient being in receipt of financial
aid for hospital costs
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allow us to adjust for potential confounders of the rela-
tionship between vitamin D status and treatment re-
sponse using multivariate analysis.
Our study also has some limitations. First, it was ob-
servational in nature; accordingly, residual confounding
cannot be excluded as an explanation for the associ-
ation between vitamin D deficiency and delayed smear
conversion that we report. Second, information on time
to sputum culture clearance was not available to us:
culture is both more sensitive and more specific than
microscopy for the detection of viable mycobacteria in
sputum, and sputum culture conversion is the only out-
come of intensive-phase treatment that has been shown
to correlate with 2-year risk of relapse [35]. Third, drug
sensitivity testing was not performed for all M. tubercu-
losis isolates, due to limited availability of resources.
However, sensitivity testing was performed in patients
at risk of drug-resistance (i.e. those who were sputum-
smear positive after 2 weeks of intensive-phase anti-TB
treatment, and who had either been previously treated
for tuberculosis or who were known to have had con-
tact with patients with confirmed MDR-TB). These cri-
teria are used in day-to-day clinical practice at Gulab
Devi Chest Hospital, and have proven to be sensitive
for the identification of patients with drug-resistant
tuberculosis: thus, there is a rationale for assuming
that patients who did not fulfil these criteria are
likely to have drug-sensitive disease.
Conclusion
In conclusion, we report that profound vitamin D defi-
ciency is highly prevalent among pulmonary TB patients
in Lahore, Pakistan, and that this associates with mark-
edly delayed sputum smear conversion in a genotype-
independent manner. Our study adds to the growing
body of literature pointing to inadequate vitamin D sta-
tus as a correctable risk factor for delayed response to
antituberculous therapy.
Table 4 Influence of vitamin D status on time to sputum smear conversion by genetic sub–groups
SNP, Gene Genotype N Adjusted HR for 25(OH)D <25
vs. ≥25 nmol/L (95 % CI)a
P HR, interaction term (95 % CI) Pinteraction
b
rs731236, VDR AA 84 5.87 (3.20–10.76) <0.001 0.84 (0.56–1.24) 0.37
AG 117 4.27 (2.65–6.86) <0.001
GG 29 5.53 (1.92–15.94) <0.001
rs1544410,VDR CC 53 5.97 (2.73–13.04) <0.001 0.79 (0.53–1.17) 0.24
CT 128 4.45 (2.81–7.05) <0.001
TT 54 4.61 (2.25–9.43) <0.001
rs2228570,VDR GG 138 6.53 (3.99–10.66) <0.001 0.61 (0.38–0.96) 0.03
GA 83 3.02 (1.82–5.01) <0.001
AA 15 4.58 (0.56–37.25) 0.16
rs7041,DBP AA 55 4.81 (2.49–9.32) <0.001 1.0 (0.69–1.45) 0.98
AC 106 6.39 (3.61–11.30) <0.001
CC 71 3.29 (1.86–5.83) <0.001
rs4588,DBP GG 122 3.65 (2.32–5.75) <0.001 1.09 (0.70–1.68) 0.69
GT 91 6.46 (3.60–11.59) <0.001
TT 21 3.92 (3.60–5.78) <0.001
rs10500804,CYP2R1 GG 59 4.46 (2.28–8.71) <0.001 1.06 (0.71–1.58) 0.76
GT 120 4.69 (2.89–7.61) <0.001
TT 52 5.38 (2.35–12.31) <0.001
rs2060793,CYP2R1 AA 10 4.47 (0.81–24.47) 0.084 0.86 (0.54–1.36) 0.53
AG 106 6.79 (3.86–11.94) <0.001
GG 112 4.10 (2.52–6.68) <0.001
rs10766197,CYP2R1 AA 52 4.15 (2.08–8.29) <0.001 1.03 (0.68–1.54) 0.88
AG 124 5.12 (3.15–8.32) <0.001
GG 56 4.82 (2.25–10.30) <0.001
SNP single nucleotide polymorphism, HR hazard ratio, 25(OH)D 25–hydroxyvitamin D, CI confidence interval, VDR vitamin D receptor, CYP2R1 vitamin D
25–hydroxylase, DBP vitamin D binding protein
aadjusted for drug sensitivity profile; bnone of these were significant using a Benjamini and Hochberg procedure controlling the false discovery rate at 20 %
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